https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial. The results were announced today at the annual meeting of the American Diabetes Association and published in … Read more
While injected GLP-1 drugs are incredibly effective at spurring weight loss, they also come with some downsides. There can be gastrointestinal side effects and loss of muscle mass. The drugs are also expensive, at $1,000 a month or more in the US before insurance. Drug companies are interested in developing anti-obesity pills because of their … Read more
FIRST ON FOX: Sen. Josh Hawley, R-Mo., introduced legislation Tuesday to scale back the popular abortion drug mifepristone after a recent study revealed that 1 in 10 women who used the medication experienced “serious adverse effects.” The Restoring Safeguards for Dangerous Abortion Drugs Act would direct the Food and Drug Administration (FDA) to create safeguards … Read more
As of this writing, Eli Lilly & Co. (LLY) is up 16.34% on the day, making it one of the biggest gainers in the market today. The surge comes after a positive update from Bloomberg regarding its experimental weight-loss pill, orforglipron. The trial results showed that patients lost an average of 7.9% of their body … Read more
Kena Betancur | Corbis News | Getty Images Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient did not experience any liver-related symptoms or side effects, a Pfizer spokesperson said … Read more
The drug is based on research conducted at MIT by Giovanni Traverso, a gastroenterologist and mechanical engineer, and Robert Langer, a chemical engineer who has launched more than two dozen biotech companies. The two discovered the mechanism when working on a way to develop liquid drug formulations that could be given to children. They soon … Read more
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four … Read more
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025. Gam1983/Getty Images
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4